Qiagen Forms Subsidiary in India | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today said that it has established a subsidiary in New Delhi, India, to sell its products directly to the Indian market.

The firm had been using distributors for its products in the country, but it believes setting up the new subsidiary will further its growth in the emerging market.

Qiagen expects the New Delhi office will have more than 30 employees by the end of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.